Table 1. Baseline demographic and clinical characteristics of patients.
| Clinical data | (N=32) | |
|---|---|---|
| Age, years (mean±SD) | 61±9 | |
| Male (%) | 59.4 | |
| BMI, kg/m2 (mean±SD) | 29.1±4.0 | |
| AC, cm (mean±SD) | 100.6±10.0 | |
| Resting HR, bpm (mean±SD) | 61±7 | |
| SBP, mmHg (mean±SD) | 124±16 | |
| DBP, mmHg (mean±SD) | 77±11 | |
| Past medical history (%) | ||
| Hypertension | 75.0 | |
| Diabetes mellitus | 71.9 | |
| Hyperlipidemia | 93.8 | |
| Previous smoking | 71.9 | |
| Obesity | 34.4 | |
| Family history of CAD | 56.3 | |
| Previous acute myocardial infarction | 75.0 | |
| CAD diagnostic time, years (mean±SD) | 12±9 | |
| Echocardiographic LVEF, % (mean±SD) | 54±9 | |
| CAD obstructive pattern (%) | ||
| One-vessel disease | 6.3 | |
| Two-vessel disease | 12.5 | |
| Three-vessel disease | 81.3 | |
| Laboratory findings (mean±SD) | ||
| LDL-cholesterol, mg/dL | 78.0±26.5 | |
| HDL-cholesterol, mg/dL | 44.3±12.9 | |
| Triglycerides, mg/dL | 129.6±54.3 | |
| HBA1C, % | 7.2±1.7 | |
| Antianginal drugs in use (%) | ||
| β-blockers | 100 | |
| Calcium channel blockers | 84.4 | |
| Long-acting nitrates | 93.8 | |
| Trimetazidine | 96.9 | |
| Ivabradine | 15.6 | |
AC: abdominal circumference; BMI: body mass index; CAD: coronary artery disease; DBP: diastolic blood pressure; HR: heart rate; LVEF: left ventricular ejection fraction; SBP: systolic blood pressure; SD: standard deviation.